Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 From the Ongoing EVERLAST-A Trial on April 27, 2026

Why It Matters

Week 16 outcomes will indicate whether ORKA‑001 can deliver durable, high‑clearance results on an ultra‑rare dosing schedule, a breakthrough that could reshape psoriasis therapy and drive Oruka’s market valuation.

Key Takeaways

• ORKA-001 targets moderate-to-severe plaque psoriasis in Phase 2a trial
• Week 16 results will be disclosed on April 27, 2026, 8 a.m. ET
• ORKA aims for annual or biannual dosing for complete clearance
• Positive data could boost Oruka’s Nasdaq valuation and partnership prospects

Pulse Analysis

The global psoriasis market, valued at roughly $15 billion, remains fragmented with biologics that require frequent injections and carry high long‑term costs. Patients and payers alike seek therapies that can sustain clear skin while minimizing administration burden. Oruka’s ORKA‑001 promises a paradigm shift by targeting core inflammatory pathways and offering dosing intervals of once or twice yearly, potentially reducing clinic visits and improving adherence.

EVERLAST‑A is a double‑blind, placebo‑controlled Phase 2a study enrolling patients with moderate‑to‑severe plaque psoriasis. The trial’s primary endpoint focuses on the proportion of participants achieving a 90 % improvement in the Psoriasis Area and Severity Index (PASI 90) by Week 16. Early signals from similar antibody platforms suggest that extended dosing can maintain efficacy, but robust data are essential to confirm durability and safety. Investors will scrutinize the Week 16 readout for both efficacy metrics and any emerging adverse events that could affect the drug’s risk‑benefit profile.

For the biotech sector, a positive readout could accelerate Oruka’s path to Phase 3, attract strategic alliances, and lift its Nasdaq‑listed shares, which have been volatile amid broader market uncertainty. Conversely, modest or negative results may prompt a reassessment of the dosing strategy and competitive positioning against established players like AbbVie and Novartis. Regardless of outcome, the data will inform the broader conversation about ultra‑long‑acting biologics and set a benchmark for future dermatology pipelines.